hollywood casino penn national drug test

Initiates 2023 Guidance – Full Year Revenue Range of $6.15 billion to $6.58 billion and Adjusted EBITDAR Range of $1.875 billion to $2.0 billionįor further information, the Company has posted a presentation to its website regarding the fourth quarter highlights and accomplishments, which can be found here. Repurchased $91.0 million of Common Stock at an Average Price of $31.69 Under the February 2022 Share Repurchase Authorization Interactive Segment Achieves Profitable Quarter

Strong Conclusion to Fourth Quarter Retail Operations Momentum Continues Into January Omni-Channel, Tech-Forward Engagement Delivering Tangible Benefits Net income of $20.8 million and net income margin of 1.3%, as compared to net income of $44.8 million and net income margin of 2.8% in the prior year Īdjusted EBITDAR of $468.3 million, a decrease of 2.5% year-over-year Īdjusted EBITDA of $438.3 million an increase of 18.8% year-over-year andĪdjusted EBITDAR margins of 29.5%, a decline of 110bps year-over-year. Revenues of $1.6 billion, an increase of 0.8% year-over-year

('PENN' or the 'Company') (Nasdaq: PENN) today reported financial results for the three months and year ended December 31, 2022. WYOMISSING, Pa., February 02, 2023-( BUSINESS WIRE)-PENN Entertainment, Inc.

Hollywood casino penn national drug test